肥酸对MASH中HDL功能的影响因糖尿病状况而异
Chunki Kim1, Tsung-Heng Tsai2, Rocio Lopez3
1Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Lipids
|July 16, 2024
概括
肥酸 (OCA) 改善了与代谢功能障碍相关的脂肪肝炎 (MASH),但在糖尿病患者和非糖尿病患者中影响HDL功能不同. 这表明不同的心血管疾病风险需要进一步研究.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 和动脉样硬化共享炎症和氧化应激路径.
- 肥酸 (OCA) 是法尔内索伊德X受体 (FXR) 激动剂,对MASH具有前景,但可能通过降低HDL胆固醇增加心血管疾病 (CVD) 风险.
研究的目的:
- 研究OCA对MASH患者的HDL胆固醇流量,抗氧化能力和促炎指数的影响,比较糖尿病和非糖尿病患者.
- 评估糖尿病和非糖尿病MASH患者之间OCA对心血管风险标志物的影响的潜在差异.
主要方法:
- 在OCA治疗18个月之前和之后,评估了MASH患者 (10名糖尿病患者,10名非糖尿病患者) 的高密度胆固醇排泄功能,抗氧化剂 (阳氧酶,血红活性),促炎指数和颗粒大小.
- 不包括服用降脂药物的患者.
- 分析了治疗后的基线费里水平和HDL功能标记物和肝酶的变化.
主要成果:
- 在非糖尿病患者中,OCA改善了肝脏组织学和酶,但增加了性酸酶.
- OCA没有显著改变胆固醇排放或偏氧酶功能.
- 在非糖尿病患者中,OCA降低了血清胺活性,并增加了HDL的炎症指数.
- 在糖尿病患者中,OCA增加了保护性pre-β-HDL水平,但没有改变HDL的整体功能.
- 血清葡萄糖水平与OCA诱导的HDL促炎功能变化有负相关性,主要是由于糖尿病.
结论:
- 在糖尿病患者和非糖尿病MASH患者中,OCA对HDL功能表现出明显的影响.
- 对HDL的差异影响可能会影响心血管疾病风险,特别是在非糖尿病MASH患者中.
- 需要进一步的大规模研究来证实这些初步发现并阐明临床影响.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
621
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
621
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
418
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Heart Failure Drugs: Inotropic Agents
563
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
563


